Clinical Trial

Efficacy of Myelofibrosis Treatments

Study Description

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Ruxolitinib

Tablet; Oral

Drug - Navitoclax

Tablet; Oral

Additional Information

Official Study Title

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis

Clinical Trial ID

NCT03222609

ParticipAid ID

QeZB6e